secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010308
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity reports Q1 net loss $37.0M; VIKTORIA-1 WT data expected Q3 2025
------------------------------------------------------------------------

- Net loss of $37.0M ($0.86/sh) vs $21.6M ($0.64/sh) in Q1 2024; non-GAAP adj. net loss $34.7M ($0.81/sh).
- Cash, cash equivalents and investments of ~$206M at March 31, 2025, expected to fund operations through 2026.
- VIKTORIA-1 PIK3CA wild-type cohort topline data now anticipated in Q3 2025; mutant cohort data in Q4 2025.
- VIKTORIA-2 Phase 3 first patient dosing on track for Q2 2025; CELC-G-201 Phase 1b data expected late Q2 2025.
- Clinical trial collaboration initiated with Dana Farber and Mass General for gedatolisib in endometrial cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000164117225010308/0001641172-25-010308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000164117225010308/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer